This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Impavido

Knight Therapeutics Inc.

Drug Names(s): hexadecylphosphocholine

Description: Impavido is a formulation of miltefosine, an inhibitor of phosphatidylcholine synthesis. Phosphatidylcholine is an important component of cell membrane and its inhibition leads to cellular apoptosis. Impavido is effective at eradicating visceral infections of Leishmania, however, the mechanism of this anti-protozoal effect is still unclear.

Deal Structure: AEterna Zentaris and Paladin Labs
In March 2008, AEterna Zentaris and Paladin Labs announced that the Companies entered into a definitive purchase and sale agreement with respect to all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine for an aggregate purchase price of Cdn$9.125 million payable in cash, subject to certain post-closing purchase price adjustments. In April 2008, AEterna Zentaris and Paladin Labs completed the transactions under their previously announced purchase and sale agreement.

Endo and Paladin
In November 2013, Endo announced that it has reached a definitive agreement to acquire Paladin in a stock and cash transaction valued at approximately $1.6 billion of which approximately 98% will be paid in shares of stock. Pursuant to the acquisition, each of Endo and Paladin will be acquired by a newly-formed Irish holding company (New Endo). Following completion of the transaction, New Endo...See full deal structure in Biomedtracker


Impavido News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug